Biocryst Pharmaceuticals Inc Quick Ratio (BCRX) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Biocryst Pharmaceuticals Inc   (NASDAQ: BCRX)

Biocryst Pharmaceuticals Inc 's Quick Ratio

BCRX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Biocryst Pharmaceuticals Inc 's Cash & cash equivalent grew by 47.66 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Biocryst Pharmaceuticals Inc 's Quick Ratio to 1.69, Quick Ratio remained below Biocryst Pharmaceuticals Inc average.

Within Biotechnology & Pharmaceuticals industry 96 other companies have achieved higher Quick Ratio than Biocryst Pharmaceuticals Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1031 to 1391.

Explain Quick Ratio?
How much Cash & cash equivalents BCRX´s has?
What are BCRX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BCRX Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 17.89 % 39.71 % 22.25 % 23.88 % 37.26 %
Y / Y Cash & cash equivalent Change 35.6 % -19 % -14.36 % -35.48 % -4.85 %
Quick Ratio MRQ 1.69 1.22 1.4 1.12 1.47
BCRX's Total Ranking # 1391 # 1031 # 750 # 1342 # 328
Seq. Current Liabilities Change 6.89 % -0.34 % 3.06 % 7.38 % 26.67 %
Seq. Cash & cash equivalent Change 47.66 % -12.98 % 28.81 % -18.07 % -11.8 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 97
Healthcare Sector # 539
Overall Market # 1391


Quick Ratio Statistics
High Average Low
5.52 2.2 0.6
(Mar 31 2022)   (Mar 31 2016)




Financial Statements
Biocryst Pharmaceuticals Inc 's Current Liabilities $ 209 Millions Visit BCRX's Balance sheet
Biocryst Pharmaceuticals Inc 's Cash & cash equivalent $ 353 Millions Visit BCRX's Balance sheet
Source of BCRX's Sales Visit BCRX's Sales by Geography


Cumulative Biocryst Pharmaceuticals Inc 's Quick Ratio

BCRX's Quick Ratio for the trailling 12 Months

BCRX Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 25.29 % 30.19 % 24.94 % 20.83 % 28.84 %
Y / Y Cash & cash equivalent TTM Growth -10.5 % -19.07 % -17.38 % -18.25 % -13.86 %
Quick Ratio TTM 1.37 1.3 1.48 1.63 1.91
Total Ranking TTM # 3958 # 3833 # 1931 # 2951 # 996
Seq. Current Liabilities TTM Growth 4.18 % 7.9 % 5.34 % 5.81 % 8.25 %
Seq. Cash & cash equivalent TTM Growth 9.39 % -5.37 % -4.23 % -9.72 % -1.09 %

Quick ratio ranking by company, industry and sector >> Back to BCRX Financial Strength Comparisons >> Go to Compare BCRX Quick Ratio to its Competitors

On the trailing twelve months basis BCRX Cash & cash equivalent grew by 35.6 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Biocryst Pharmaceuticals Inc 's Quick Ratio to 1.37, Quick Ratio remained below BCRX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 142 other companies have achieved higher Quick Ratio than Biocryst Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3833 to 3958.

Explain Quick Ratio?
How much Cash & cash equivalents BCRX´s has?
What are BCRX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 143
Healthcare Sector # 894
Within the Market # 3958


trailing twelve months Quick Ratio Statistics
High Average Low
4.99 2.18 0.79
(Sep 30 2022)   (Sep 30 2016)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Replimune Group Inc   4.57 $ 195.328  Millions$ 42.767  Millions
Recursion Pharmaceuticals Inc   4.55 $ 545.683  Millions$ 119.886  Millions
Prime Medicine Inc   4.50 $ 142.720  Millions$ 31.692  Millions
Immunitybio inc   4.50 $ 357.371  Millions$ 79.392  Millions
Dbv Technologies S a   4.37 $ 174.900  Millions$ 40.000  Millions
Metagenomi Therapeutics Inc   4.37 $ 120.700  Millions$ 27.632  Millions
Alpha Cognition Inc.  4.37 $ 41.443  Millions$ 9.493  Millions
Intensity Therapeutics Inc   4.23 $ 9.500  Millions$ 2.245  Millions
Ginkgo Bioworks Holdings Inc   4.15 $ 302.163  Millions$ 72.740  Millions
Dyadic International Inc   4.13 $ 16.047  Millions$ 3.883  Millions
Tenaya Therapeutics Inc   4.11 $ 78.100  Millions$ 19.021  Millions
Vir Biotechnology Inc   4.08 $ 530.522  Millions$ 130.177  Millions
Adaptive Biotechnologies Corporation  3.92 $ 344.255  Millions$ 87.712  Millions
Immunocore Holdings Plc  3.74 $ 880.211  Millions$ 235.198  Millions
Entera Bio Ltd   3.50 $ 11.309  Millions$ 3.235  Millions
Exozymes Inc   3.49 $ 5.653  Millions$ 1.618  Millions
Acumen Pharmaceuticals Inc   3.44 $ 160.954  Millions$ 46.848  Millions
Century Therapeutics inc   3.29 $ 49.642  Millions$ 15.068  Millions
Adma Biologics Inc   3.26 $ 136.020  Millions$ 41.690  Millions
Tscan Therapeutics Inc   3.23 $ 100.156  Millions$ 30.964  Millions
Sutro Biopharma Inc   3.11 $ 164.346  Millions$ 52.898  Millions
Editas Medicine Inc   3.09 $ 211.645  Millions$ 68.434  Millions
Autolus Therapeutics Plc  2.93 $ 201.630  Millions$ 68.790  Millions
Moderna Inc   2.73 $ 6,910.000  Millions$ 2,534.000  Millions
Sana Biotechnology Inc   2.59 $ 320.990  Millions$ 123.752  Millions
Tarsus Pharmaceuticals Inc   2.56 $ 449.690  Millions$ 175.753  Millions
Meiragtx Holdings Plc  2.46 $ 143.166  Millions$ 58.096  Millions
Kodiak Sciences Inc   2.39 $ 125.903  Millions$ 52.770  Millions
Exelixis Inc   2.32 $ 839.385  Millions$ 361.927  Millions
Precision Biosciences Inc  2.19 $ 87.549  Millions$ 39.886  Millions

Date modified: 2026-09-09T22:24:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.